Sterling Capital Management LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 570.8% in the 3rd quarter, Holdings Channel reports. The firm owned 5,199 shares of the biopharmaceutical company’s stock after acquiring an additional 4,424 shares during the period. Sterling Capital Management LLC’s holdings in Halozyme Therapeutics were worth $574,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HALO. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after purchasing an additional 1,052,509 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $196,540,000. Royal London Asset Management Ltd. raised its holdings in shares of Halozyme Therapeutics by 12.4% during the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after buying an additional 200,262 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $105,570,000. 97.79% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Halozyme Therapeutics news, Director Matthew L. Posard sold 5,230 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the transaction, the director directly owned 53,609 shares in the company, valued at approximately $5,818,720.86. This trade represents a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $83,995,132. The trade was a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock worth $13,538,046 in the last 90 days. Insiders own 2.50% of the company’s stock.
Halozyme Therapeutics Stock Performance
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period in the prior year, the business earned $1.54 earnings per share. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently weighed in on HALO shares. HC Wainwright upped their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Citizens Jmp raised their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Stifel Nicolaus set a $130.00 target price on Halozyme Therapeutics in a research note on Friday, October 16th. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $99.55.
Read Our Latest Research Report on HALO
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.
Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.
Read More
- Five stocks we like better than Halozyme Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
